DarshanTalks Podcast

Send us Fan Mail

We discuss the 7 things to do before closing your pharmacy:

1. Return your DEA registration,
2. Notify the Board of Pharmacy,
3. Dispose of controlled substances appropriately,
4. Inventory your pharmacy and create a clear inventory list,
5. Keep all documentation, especially for controlled substances, for at least 2 years,
6. Know where your records are stored, as the DEA may request them later and
7. Contact the Board to let them know that you will be transferring documentation and any drugs and/or devices.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The FDA's recent decision to cease its enforcement discretion for lab-developed tests (LDTs) has significant implications for developers. To ensure compliance, developers must adhere to a rigorous process.
 
Key steps include:
1) Develop a risk-based framework- 0:39- 1:03
2) Get pre-market clearance or approval- 1:04- 1:37
3) Quality control and quality assurance- 1:38- 2:04
4) Adhering to FDA guidelines for labeling and marketing- 2:05- 2:21
5) Ensuring data security and patient privacy- 2:22- 2:43
6) Conducting post-market surveillance- 2:44- 3:03
7) Staying proactive in meeting new compliance requirements- 3:04- 3:20
 
For expert guidance on FDA approval and regulatory clearance, contact Darshan Kulkarni at 302-252-6959.
 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

On September 5th, 2023, a Miami jury found a medical clinic owner and pharmacist guilty of falsifying and fabricating clinical trial data.
 
We highlight the significance of pharmacists recognizing red flags indicating potential fraud, including patients unknowingly or involuntarily enrolled in clinical trials.
 
Beyond the broader impact on public trust, pharmacists could face specific repercussions, such as disciplinary actions from the State Board of Pharmacy. Moreover, clinic owners could be barred from participating in research activities.
 
Implementing robust internal controls and collaborating with law enforcement to identify and report suspected fraud are essential steps for pharmacists and clinic owners to safeguard themselves from legal ramifications.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, guest Dave Bulger delves into the intricate role of AI, questioning whether it functions as a creator, a copycat, or perhaps both. Dave Bulger, delves into the world of #AI, highlighting the distinction between AI and large language models (LLMs). He exposes the limitations of generative AI, raises concerns about copyright in content generation, and explores AI's potential impact across industries. Dave underscores that while LLMs can generate text, they lack true understanding. The conversation explores the challenges of scraping data for accuracy and ponders the future of AI, emphasizing the value of content creators and the necessity for expert verification in an AI-augmented world.

We discussed the following:

Introduction to the discussion- 1:09- 2:21

Are the tools we are using AI or LLMs?  2:23- 6:14

Can these tools replace people? 6:15- 9:45

Can you provide two descriptive comparisons that are relevant to the current state of generative AI? 9:46- 11:46

What is the current state of generative AI? 11:47- 13:05

Is there value to having different large language models?  14:26- 18:02

Why is it difficult to train these models on language using Reddit and other websites?  18:03- 19:51

What are your thoughts on content is king when we know that it's unsustainable? 19:52- 21:23

Who owns the results provided by these models? 21:41- 24:32

Should government agencies regulate AI? 24:33- 25:41

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The FDA has taken action by sending warning letters to eight companies that have been marketing unapproved eye products, potentially violating federal laws and risking consumer health. 

These companies include Boiron Inc, CVS Health, Dr. Vitamin Solutions, Natural Ophthalmics Inc., OcluMed LLC, Similasan USA or Similasan AG, TRP Company Inc., and Walgreens Boots Alliance Inc. 

These companies are now under increased scrutiny and may face legal consequences if they fail to comply with FDA regulations. They must either seek FDA approval for their products or remove them from the market to avoid further repercussions. 

Additionally, they need to establish appropriate marketing compliance programs to ensure accurate product labeling. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

FDA is suggesting the use of one-pagers to provide essential drug information to patients. Past attempts faced challenges, such as one-size-fits-all content and patient trust issues. 
 
Darshan emphasizes that while the FDA's proposal is a step in the right direction, it must ensure that these one-pagers are comprehensive, accurate, and transparent. Patients often rely on healthcare providers and trusted sources like WebMD for drug information. This short explores the potential benefits and concerns surrounding this FDA initiative, stressing the need for precise and reliable drug information.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 In this episode, we’ll discuss how to speed up your marketing approval process with these must know concept review tips. We will talk to Heather McFalls, Director of AD Promo at Organon. In this interview we will address the following questions: 
1.    How often do people do concept reviews? 
2.    Is it useful to have an attorney at the concept review stage? 
3.    Is the role of PRC advisory or quality-focused?
4.    Who owns the PRC process? 
5.     Should the PRC process be sequential or parallel? 
6.     Has AI been disruptive in the concept review process? 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 We explore the world of biohacking, with a particular focus on the emerging trend of "testosterone parties." These biohacking practices raise concerns regarding safety, efficacy, and misleading promotion, as many unapproved applications lack scientific support. It's worth noting that the FBI oversees biohacking, despite its primary purpose not being generalized research. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 AI expert Dave Bulger, delves into the world of #AI, highlighting the distinction between AI and large language models (LLMs). He exposes the limitations of generative AI, raises concerns about copyright in content generation, and explores AI's potential impact across industries. Dave underscores that while LLMs can generate text, they lack true understanding. The conversation explores the challenges of scraping data for accuracy and ponders the future of AI, emphasizing the value of content creators and the necessity for expert verification in an AI-augmented world. We discussed the following: 

1.  Are the tools we are using AI or LLMs? 
2. Can these tools replace people? 
3. Can you provide two descriptive comparisons that are relevant to the current state of generative AI? 
4. What does generative AI represent right now? 
5. Is there value to having different large language models? 
6.  Why is it difficult to train these models? 
7. Who owns the results provided by these models? 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 We explore the world of biohacking, with a particular focus on the emerging trend of "testosterone parties." These biohacking practices raise concerns regarding safety, efficacy, and misleading promotion, as many unapproved applications lack scientific support. It's worth noting that the FBI oversees biohacking, despite its primary purpose not being generalized research. 

Support the show

www.kulkarnilawfirm.com